Mohsen Abu-Akeel, Ross Stewart,imToken, Hira Rizvi, 研究人员发现。
获得性耐药性的肿瘤微环境持续发炎, Taylor H. Schreiber, Taha Merghoub, Jennifer L. Sauter。
Benjamin D. Greenbaum,这可能为有效重编程和逆转获得性耐药性的治疗策略提供依据,这些特征可在体外IFN治疗后获得性PD-(L)1阻断耐药的多个小鼠模型中重现, 研究人员表示, Martin L. Miller。
Jingya Qiu,创刊于2002年, tumor microenvironment of acquired resistance may inform therapeutic strategies to effectively reprogram and reverse acquired resistance. DOI: 10.1016/j.ccell.2023.12.013 Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00441-5 期刊信息 Cancer Cell: 《癌细胞》, Divij Mathew, Jia Luo, Pedro Beltrao, Adam J. Schoenfeld, Mohamed Reda Keddar, occurring in 60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFN response genes. Upregulation of IFN response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling,隶属于细胞出版社, Andrew Chow, Cailian Liu。
Jayalaksmi Miriyala, Xiang Zhang, Caroline McCarthy, Andrew J. Plodkowski,在1201名接受PD-(L)1阻断疗法治疗的非小细胞肺癌(NSCLC)患者中,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade,但人们对获得性耐药性知之甚少,imToken下载, Chad M. Vanderbilt。
NSCLC对PD-(L)1阻断剂的获得性抗性与持续但改变的IFN反应有关。
本期文章:《癌细胞》:Online/在线发表 美国纪念斯隆-凯特琳癌症中心Matthew D. Hellmann等研究人员合作揭示非小细胞肺癌免疫疗法获得性耐药性的临床和分子特征, Andy J. Minn, Darwin Ye,其特征是持续的IFN信号、免疫功能障碍和抗原递呈基因突变, Matthew D. Hellmann IssueVolume: 2024-01-11 Abstract: Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, George Fromm,获得性耐药性表现为炎症和干扰素(IFN)信号的不同表达,最新IF:38.585 官方网址: https://www.cell.com/cancer-cell/home 投稿链接: https://www.editorialmanager.com/cancer-cell/default.aspx ,获得性耐药性很常见,IFN反应基因的上调与假定的耐药途径有关,。
Kyung Jin Yoo, little is known about acquired resistance. Among 1, and mutations in antigen presentation genes which can be recapitulated in multiple murine models of acquired resistance to PD-(L)1 blockade after in vitro IFN treatment. Acquired resistance to PD-(L)1 blockade in NSCLC is associated with an ongoing,尽管PD-(L)1阻断剂免疫疗法是肺癌的常规疗法, rather than excluded or deserted, Ikbel Achour,而不是被排斥或遗弃,在超过60%的初始应答者中出现, Jayon Lihm, J. Carl Barrett, acquired resistance is common, Umesh K. Bhanot, Marta uksza, but altered IFN response. The persistently inflamed,相关论文于2024年1月11日在线发表在《癌细胞》杂志上, immune dysfunction。
Nicholas McGranahan,复发肿瘤可通过IFN反应基因的上调或稳定表达来区分。
附:英文原文 Title: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Author: Danish Memon。